NexImmune Company

NexImmune is a company that is developing a novel technology platform with broad application across multiple disease areas. They are a rapidly growing leader in the emerging field of antigen-directed immunotherapies. Their vision is to conquer cancer and life-threatening immune-mediated conditions by directing natural, disease-specific immune responses. They are developing a proprietary nanotechnology platform, Artificial Immune Modulation (AIM), that employs natural biology to direct specific T cell-mediated immune responses capable of treating a variety of diseases. The AIM nanoparticles use biology similar to that of healthy dendritic cells to deliver the instructions necessary to direct healthy T cell function. Each AIM nanoparticle can be programmed to deliver customized instructions directly to specific populations of T cells, bringing pharmaceutical precision to cell therapy.

Investors

Total Funding: 210268293
Headquarters: Gaithersburg, Maryland, United States
Funding Status: IPO
Employee Number: 11-50
Estimated Revenue: $10M to $50M
Last Funding Type: Post-IPO Equity
Last Funding Date: 2021-02-17
Investors Number: 7
Founded Date: 2011-01-01
Industry: Atrificial Vectors and Immune Cells
Register and Claim Ownership